Endocrine toxicities of immune checkpoint inhibitors

Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T lymphocyte antigen 4 (CTLA4) or PD1 and its ligand PDL1. ICIs, such as nivolumab, pembrolizumab and ipilimumab,...

Full description

Saved in:

Bibliographic Details
Published in:	Nature reviews. Endocrinology Vol. 17; no. 7; pp. 389 - 399
Main Authors:	Wright, Jordan J, Powers, Alvin C, Johnson, Douglas B
Format:	Journal Article
Language:	English
Published:	England Nature Publishing Group 01.07.2021
Subjects:	Adrenal glands Adverse events Antineoplastic Agents, Immunological - adverse effects Cancer Cell activation CTLA-4 protein Cytotoxicity Diabetes mellitus Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - immunology Endocrine disorders Endocrine System Diseases - chemically induced Endocrine System Diseases - diagnosis Endocrine System Diseases - epidemiology Endocrine System Diseases - therapy Epidemiology Humans Hypothyroidism Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune System - drug effects Immune System - physiology Immunotherapy Immunotherapy - adverse effects Lymphocytes T Monoclonal antibodies Morbidity Neoplasms - drug therapy Neoplasms - epidemiology Neoplasms - immunology Pancreas PD-1 protein Pembrolizumab Pituitary Signal transduction Thyroid Thyrotoxicosis
ISSN:	1759-5029, 1759-5037, 1759-5037
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T lymphocyte antigen 4 (CTLA4) or PD1 and its ligand PDL1. ICIs, such as nivolumab, pembrolizumab and ipilimumab, are approved for the treatment of numerous and diverse cancer types, in various combination regimens, and are now an established cornerstone of cancer therapeutics. Toxicities induced by ICIs are autoimmune in nature and are referred to as immune-related adverse events (irAEs); these events can affect any organ system in an unpredictable fashion. Importantly, irAEs can manifest as endocrinopathies involving the thyroid (hypothyroidism or thyrotoxicosis), pituitary (hypophysitis), adrenal glands (adrenal insufficiency) and pancreas (diabetes mellitus). These events are a frequent source of acute and persistent morbidity in patients treated with ICIs and can even be fatal. Over the past few years, there has been a growing understanding of the underlying pathogenesis of irAEs that has led to the development of more effective management strategies. Herein, we review the current understanding of the pathobiology, clinical manifestations and treatment approaches to endocrine toxicities arising from ICIs.
AbstractList	Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T lymphocyte antigen 4 (CTLA4) or PD1 and its ligand PDL1. ICIs, such as nivolumab, pembrolizumab and ipilimumab, are approved for the treatment of numerous and diverse cancer types, in various combination regimens, and are now an established cornerstone of cancer therapeutics. Toxicities induced by ICIs are autoimmune in nature and are referred to as immune-related adverse events (irAEs); these events can affect any organ system in an unpredictable fashion. Importantly, irAEs can manifest as endocrinopathies involving the thyroid (hypothyroidism or thyrotoxicosis), pituitary (hypophysitis), adrenal glands (adrenal insufficiency) and pancreas (diabetes mellitus). These events are a frequent source of acute and persistent morbidity in patients treated with ICIs and can even be fatal. Over the past few years, there has been a growing understanding of the underlying pathogenesis of irAEs that has led to the development of more effective management strategies. Herein, we review the current understanding of the pathobiology, clinical manifestations and treatment approaches to endocrine toxicities arising from ICIs.Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T lymphocyte antigen 4 (CTLA4) or PD1 and its ligand PDL1. ICIs, such as nivolumab, pembrolizumab and ipilimumab, are approved for the treatment of numerous and diverse cancer types, in various combination regimens, and are now an established cornerstone of cancer therapeutics. Toxicities induced by ICIs are autoimmune in nature and are referred to as immune-related adverse events (irAEs); these events can affect any organ system in an unpredictable fashion. Importantly, irAEs can manifest as endocrinopathies involving the thyroid (hypothyroidism or thyrotoxicosis), pituitary (hypophysitis), adrenal glands (adrenal insufficiency) and pancreas (diabetes mellitus). These events are a frequent source of acute and persistent morbidity in patients treated with ICIs and can even be fatal. Over the past few years, there has been a growing understanding of the underlying pathogenesis of irAEs that has led to the development of more effective management strategies. Herein, we review the current understanding of the pathobiology, clinical manifestations and treatment approaches to endocrine toxicities arising from ICIs. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T lymphocyte antigen 4 (CTLA4) or PD1 and its ligand PDL1. ICIs, such as nivolumab, pembrolizumab and ipilimumab, are approved for the treatment of numerous and diverse cancer types, in various combination regimens, and are now an established cornerstone of cancer therapeutics. Toxicities induced by ICIs are autoimmune in nature and are referred to as immune-related adverse events (irAEs); these events can affect any organ system in an unpredictable fashion. Importantly, irAEs can manifest as endocrinopathies involving the thyroid (hypothyroidism or thyrotoxicosis), pituitary (hypophysitis), adrenal glands (adrenal insufficiency) and pancreas (diabetes mellitus). These events are a frequent source of acute and persistent morbidity in patients treated with ICIs and can even be fatal. Over the past few years, there has been a growing understanding of the underlying pathogenesis of irAEs that has led to the development of more effective management strategies. Herein, we review the current understanding of the pathobiology, clinical manifestations and treatment approaches to endocrine toxicities arising from ICIs. Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling pathways related to T cell activation and exhaustion, by binding to and inhibiting cytotoxic T lymphocyte antigen 4 (CTLA4) or PD1 and its ligand PDL1. ICIs, such as nivolumab, pembrolizumab and ipilimumab, are approved for the treatment of numerous and diverse cancer types, in various combination regimens, and are now an established cornerstone of cancer therapeutics. Toxicities induced by ICIs are autoimmune in nature and are referred to as immune-related adverse events (irAEs); these events can affect any organ system in an unpredictable fashion. Importantly, irAEs can manifest as endocrinopathies involving the thyroid (hypothyroidism or thyrotoxicosis), pituitary (hypophysitis), adrenal glands (adrenal insufficiency) and pancreas (diabetes mellitus). These events are a frequent source of acute and persistent morbidity in patients treated with ICIs and can even be fatal. Over the past few years, there has been a growing understanding of the underlying pathogenesis of irAEs that has led to the development of more effective management strategies. Herein, we review the current understanding of the pathobiology, clinical manifestations and treatment approaches to endocrine toxicities arising from ICIs.Immune checkpoint inhibitors (ICIs) are now an established cornerstone of cancer therapeutics; however, ICIs are associated with toxicities in various organs, termed immune-related adverse events. This Review highlights current understanding in ICI-induced endocrinopathies, including epidemiology, aetiology, clinical manifestations and approaches to treatment.
Author	Wright, Jordan J Powers, Alvin C Johnson, Douglas B
Author_xml	– sequence: 1 givenname: Jordan J orcidid: 0000-0002-2043-0150 surname: Wright fullname: Wright, Jordan J organization: Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA – sequence: 2 givenname: Alvin C surname: Powers fullname: Powers, Alvin C organization: VA Tennessee Valley Healthcare System, Nashville, TN, USA – sequence: 3 givenname: Douglas B orcidid: 0000-0002-6390-773X surname: Johnson fullname: Johnson, Douglas B email: douglas.b.johnson@vumc.org organization: Department of Medicine, Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center, Nashville, TN, USA. douglas.b.johnson@vumc.org
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/33875857$$D View this record in MEDLINE/PubMed
BookMark	eNpd0MtKxDAUBuAgI85FX8CFFNy4qeZ-kqUM4wUG3Oi6NGnKZGyTsWlB396AowtX5_Dz8XM4SzQLMTiELgm-JZipu8SJAF5iSkqMueIlO0ELAkKXAjOY_e1Uz9EypT3GUnLgZ2jOmAKhBCwQ34Qm2sEHV4zx01s_epeK2Ba-76cc2p2z74fow1j4sPPGj3FI5-i0rbvkLo5zhd4eNq_rp3L78vi8vt-WVjI1llQ3UGPVSKk02BZ4AxgLbg1w6pgyNZHSUJtD06oGoAZoCCHUKiNaazRboZuf3sMQPyaXxqr3ybquq4OLU6qoIEIqITTL9Pof3cdpCPm6rHguZVzjrK6OajK9a6rD4Pt6-Kp-_8G-AXg3YsM
CitedBy_id	crossref_primary_10_1016_j_apsb_2024_05_032 crossref_primary_10_1080_1120009X_2024_2305065 crossref_primary_10_3390_diagnostics12092116 crossref_primary_10_1136_jitc_2022_006500 crossref_primary_10_3389_fonc_2024_1381250 crossref_primary_10_1016_j_ejca_2023_01_034 crossref_primary_10_1038_s41572_022_00357_7 crossref_primary_10_7861_clinmed_2022_0589 crossref_primary_10_7759_cureus_50272 crossref_primary_10_3390_biomedicines11010107 crossref_primary_10_1186_s12943_025_02225_w crossref_primary_10_1016_S1155_1941_24_46693_6 crossref_primary_10_1210_clinem_dgad457 crossref_primary_10_1007_s00262_023_03498_0 crossref_primary_10_1210_clinem_dgae664 crossref_primary_10_1016_j_toxrep_2025_102033 crossref_primary_10_1093_jjco_hyad034 crossref_primary_10_3803_EnM_2024_2180 crossref_primary_10_1055_a_2318_7637 crossref_primary_10_3390_diagnostics13101812 crossref_primary_10_1080_1744666X_2023_2221434 crossref_primary_10_1016_j_cpt_2023_11_005 crossref_primary_10_3238_PersDia_2025_06_27_01 crossref_primary_10_4103_ni_ni_1070_21 crossref_primary_10_1007_s11428_024_01148_2 crossref_primary_10_1210_clinem_dgac359 crossref_primary_10_3390_cancers16233929 crossref_primary_10_1016_j_canlet_2025_217504 crossref_primary_10_1016_j_iac_2021_12_006 crossref_primary_10_1016_j_ijheh_2022_114049 crossref_primary_10_3390_cancers15010246 crossref_primary_10_1210_jcemcr_luad025 crossref_primary_10_3390_medicina59020215 crossref_primary_10_1186_s12902_025_01986_1 crossref_primary_10_1097_MD_0000000000035506 crossref_primary_10_3390_cancers14030593 crossref_primary_10_1016_j_mmm_2022_06_004 crossref_primary_10_1097_CAD_0000000000001739 crossref_primary_10_1007_s13340_024_00703_y crossref_primary_10_1007_s12020_024_03718_2 crossref_primary_10_1097_MED_0000000000000664 crossref_primary_10_1007_s00432_023_04659_5 crossref_primary_10_1002_advs_202305150 crossref_primary_10_3892_ol_2024_14577 crossref_primary_10_1177_10732748251381428 crossref_primary_10_3390_jcm12155161 crossref_primary_10_7759_cureus_44296 crossref_primary_10_1111_bph_70195 crossref_primary_10_3389_fimmu_2024_1392956 crossref_primary_10_1007_s12020_025_04164_4 crossref_primary_10_3390_cancers17091571 crossref_primary_10_1007_s13340_023_00659_5 crossref_primary_10_1007_s00262_023_03522_3 crossref_primary_10_15212_AMM_2023_0037 crossref_primary_10_1055_a_2318_7541 crossref_primary_10_5415_apallergy_0000000000000146 crossref_primary_10_1016_j_ejca_2021_08_038 crossref_primary_10_1016_j_rmclc_2025_06_001 crossref_primary_10_1055_a_2267_1634 crossref_primary_10_1016_j_annonc_2022_10_001 crossref_primary_10_1111_imr_13249 crossref_primary_10_1097_MED_0000000000000652 crossref_primary_10_1097_MD_0000000000037387 crossref_primary_10_1186_s12902_023_01397_0 crossref_primary_10_2217_imt_2021_0316 crossref_primary_10_3389_fendo_2025_1584675 crossref_primary_10_1007_s40618_025_02659_5 crossref_primary_10_1055_a_2544_9630 crossref_primary_10_1007_s44178_023_00040_1 crossref_primary_10_1016_j_bbcan_2023_188928 crossref_primary_10_1016_j_ecl_2025_06_009 crossref_primary_10_4103_ijmr_IJMR_313_19 crossref_primary_10_1210_clinem_dgac689 crossref_primary_10_3389_fendo_2023_1100007 crossref_primary_10_1136_jitc_2021_002627 crossref_primary_10_1007_s12020_024_04050_5 crossref_primary_10_3390_cancers14215426 crossref_primary_10_1097_MNH_0000000000000960 crossref_primary_10_1007_s10049_025_01473_z crossref_primary_10_21802_artm_2023_2_26_238 crossref_primary_10_7759_cureus_91338 crossref_primary_10_1016_j_therap_2023_09_010 crossref_primary_10_3390_jpm14040431 crossref_primary_10_1038_s41392_023_01521_5 crossref_primary_10_1148_rg_220108 crossref_primary_10_1055_a_1980_0164 crossref_primary_10_3389_fimmu_2024_1405856 crossref_primary_10_1007_s15004_025_0957_2 crossref_primary_10_1007_s11864_022_00995_9 crossref_primary_10_3389_fphar_2021_710943 crossref_primary_10_1210_clinem_dgaf260 crossref_primary_10_1038_s41598_024_69944_w crossref_primary_10_3389_fmolb_2022_961450 crossref_primary_10_3892_ol_2025_15023 crossref_primary_10_4240_wjgs_v17_i2_100257 crossref_primary_10_1016_S2213_8587_24_00283_3 crossref_primary_10_1097_MPA_0000000000002337 crossref_primary_10_1007_s00125_022_05666_w crossref_primary_10_1210_jendso_bvad017 crossref_primary_10_1016_j_prp_2023_154688 crossref_primary_10_1016_j_coi_2025_102556 crossref_primary_10_3892_ol_2023_14083 crossref_primary_10_3390_endocrines2020012 crossref_primary_10_7759_cureus_26859 crossref_primary_10_1073_pnas_2409266122 crossref_primary_10_1016_j_bbcan_2024_189162 crossref_primary_10_59324_ejmhr_2025_3_5__02 crossref_primary_10_53011_JMRO_2024_01_08 crossref_primary_10_1038_s41392_022_01102_y crossref_primary_10_3389_fimmu_2022_1019772 crossref_primary_10_3389_fimmu_2025_1548452 crossref_primary_10_1186_s12916_024_03812_2 crossref_primary_10_1007_s00432_023_05364_z crossref_primary_10_1007_s44337_025_00342_5 crossref_primary_10_1159_000537969 crossref_primary_10_1007_s11892_021_01435_y crossref_primary_10_3389_fimmu_2022_1083840 crossref_primary_10_1111_cas_16352 crossref_primary_10_1186_s13256_023_04248_7 crossref_primary_10_3389_fmicb_2022_998058 crossref_primary_10_1016_j_semcdb_2023_10_007 crossref_primary_10_1097_MD_0000000000037587 crossref_primary_10_3389_fimmu_2023_1167975 crossref_primary_10_1186_s13046_022_02568_y crossref_primary_10_3389_fonc_2022_1021713 crossref_primary_10_2147_CMAR_S444916 crossref_primary_10_3390_cancers16122287 crossref_primary_10_1016_j_eprac_2024_08_012 crossref_primary_10_3389_fonc_2025_1642893 crossref_primary_10_3390_cancers17172728 crossref_primary_10_1007_s12022_023_09771_3 crossref_primary_10_1007_s13340_025_00795_0 crossref_primary_10_1016_j_esmorw_2024_100061 crossref_primary_10_1007_s12020_024_03859_4 crossref_primary_10_1016_j_asjsur_2024_11_134 crossref_primary_10_7759_cureus_82701 crossref_primary_10_1016_j_rce_2024_10_004 crossref_primary_10_1371_journal_pone_0281983 crossref_primary_10_1210_clinem_dgab672 crossref_primary_10_3389_fimmu_2022_844142 crossref_primary_10_1212_CON_0000000000001359 crossref_primary_10_1097_MED_0000000000000806 crossref_primary_10_1097_RLU_0000000000005440 crossref_primary_10_1097_CMR_0000000000000998 crossref_primary_10_1097_CJI_0000000000000555 crossref_primary_10_3389_fonc_2025_1547387 crossref_primary_10_3390_medicina59111963 crossref_primary_10_3389_fphar_2024_1341612 crossref_primary_10_3389_fimmu_2023_1323797 crossref_primary_10_1016_j_beem_2022_101668 crossref_primary_10_3389_fimmu_2022_929846 crossref_primary_10_3389_fendo_2024_1253832 crossref_primary_10_1136_jclinpath_2021_207895 crossref_primary_10_3389_fphar_2025_1622339 crossref_primary_10_3390_cancers16091764 crossref_primary_10_1016_j_clbc_2025_03_004 crossref_primary_10_3389_fmed_2023_1222543 crossref_primary_10_1080_14740338_2022_2134343 crossref_primary_10_3389_fimmu_2025_1625738 crossref_primary_10_3389_fgene_2022_1104338 crossref_primary_10_1080_17512433_2024_2431513 crossref_primary_10_1016_j_omtn_2022_04_030 crossref_primary_10_3390_diseases12020040 crossref_primary_10_1038_s41574_024_01077_6 crossref_primary_10_3390_pharmaceutics15030823 crossref_primary_10_1186_s12890_024_03140_4 crossref_primary_10_3389_fimmu_2025_1571247 crossref_primary_10_3389_fonc_2022_981084 crossref_primary_10_2174_0929867328666211115122324 crossref_primary_10_3389_fimmu_2021_721830 crossref_primary_10_1080_14740338_2024_2446422 crossref_primary_10_1016_j_intimp_2024_111926 crossref_primary_10_1007_s00262_022_03151_2 crossref_primary_10_1097_JS9_0000000000002528 crossref_primary_10_7759_cureus_89689 crossref_primary_10_1080_2162402X_2023_2188719 crossref_primary_10_3389_fendo_2022_1010279 crossref_primary_10_3892_ol_2024_14849 crossref_primary_10_1002_adhm_202401538 crossref_primary_10_1177_23247096231194401 crossref_primary_10_1002_jha2_1025 crossref_primary_10_1016_j_eprac_2024_11_012 crossref_primary_10_3390_cancers17030436 crossref_primary_10_1016_j_canep_2022_102265 crossref_primary_10_1007_s00262_023_03489_1 crossref_primary_10_1007_s00432_023_05093_3 crossref_primary_10_3389_fimmu_2023_1229823 crossref_primary_10_3389_fphar_2025_1426847 crossref_primary_10_7759_cureus_80083 crossref_primary_10_1016_j_modpat_2024_100683 crossref_primary_10_1007_s11912_023_01462_w crossref_primary_10_1371_journal_pone_0294227 crossref_primary_10_1007_s11060_023_04382_8 crossref_primary_10_1159_000545957 crossref_primary_10_1111_cen_14788 crossref_primary_10_1089_thy_2022_0275 crossref_primary_10_1155_2021_5300381 crossref_primary_10_3389_fimmu_2025_1583363 crossref_primary_10_3390_cancers15010173 crossref_primary_10_1016_j_radonc_2025_110943 crossref_primary_10_3390_cancers14174192 crossref_primary_10_1097_MD_0000000000043983 crossref_primary_10_1186_s12957_025_03745_x crossref_primary_10_1016_S2213_8587_24_00088_3 crossref_primary_10_1007_s11864_022_00988_8 crossref_primary_10_1210_jcemcr_luae200 crossref_primary_10_1016_j_jbo_2023_100505 crossref_primary_10_3389_fendo_2025_1589630 crossref_primary_10_1007_s12672_024_01195_7 crossref_primary_10_3389_fendo_2022_1090842 crossref_primary_10_1186_s13256_024_04375_9 crossref_primary_10_3389_fphar_2022_960323 crossref_primary_10_1016_j_rceng_2024_12_003 crossref_primary_10_1210_endrev_bnad021 crossref_primary_10_1038_s41598_025_05563_3 crossref_primary_10_3389_fendo_2023_1157805 crossref_primary_10_3389_fimmu_2025_1651088 crossref_primary_10_3389_fimmu_2022_975787 crossref_primary_10_1007_s12274_023_5477_5 crossref_primary_10_1172_JCI167728 crossref_primary_10_7759_cureus_85957 crossref_primary_10_1111_cpr_13644 crossref_primary_10_3390_ijms241411504 crossref_primary_10_1136_bcr_2023_258701 crossref_primary_10_5306_wjco_v15_i5_576 crossref_primary_10_3389_fimmu_2025_1508293 crossref_primary_10_1007_s12328_023_01775_0 crossref_primary_10_7759_cureus_92247 crossref_primary_10_1016_j_arcmed_2022_01_003 crossref_primary_10_1016_j_critrevonc_2025_104627 crossref_primary_10_1038_s41571_025_01029_7 crossref_primary_10_1007_s00262_024_03852_w crossref_primary_10_1007_s00259_025_07364_2 crossref_primary_10_1016_j_mpmed_2025_07_013 crossref_primary_10_1111_1759_7714_14660 crossref_primary_10_1177_10781552241255699 crossref_primary_10_7759_cureus_60565 crossref_primary_10_1007_s13340_024_00719_4 crossref_primary_10_1210_jcemcr_luaf194 crossref_primary_10_1007_s00108_024_01731_1 crossref_primary_10_1186_s40001_023_01365_3 crossref_primary_10_1136_jitc_2023_008591 crossref_primary_10_3389_fendo_2023_1213225 crossref_primary_10_3389_fendo_2024_1400841 crossref_primary_10_3390_cancers17162651 crossref_primary_10_1210_clinem_dgad260
ContentType	Journal Article
Copyright	Springer Nature Limited 2021.
Copyright_xml	– notice: Springer Nature Limited 2021.
DBID	CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FE 8FH 8FI 8FJ 8FK ABUWG AFKRA AZQEC BBNVY BENPR BHPHI CCPQU DWQXO FYUFA GHDGH GNUQQ HCIFZ K9. LK8 M0S M1P M7P PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PRINS 7X8
DOI	10.1038/s41574-021-00484-3
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest SciTech Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Natural Science Collection ProQuest One Community College ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) Biological Science Database ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) SciTech Premium Collection ProQuest One Community College ProQuest One Health & Nursing ProQuest Natural Science Collection ProQuest Central China ProQuest Central ProQuest One Applied & Life Sciences ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) Natural Science Collection ProQuest Central Korea Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) Biological Science Database ProQuest SciTech Collection ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE ProQuest Central Student
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Anatomy & Physiology
EISSN	1759-5037
EndPage	399
ExternalDocumentID	33875857
Genre	Review Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural
GrantInformation_xml	– fundername: NHLBI NIH HHS grantid: R01 HL155990 – fundername: NIDDK NIH HHS grantid: T32 DK007061 – fundername: NIDDK NIH HHS grantid: P30 DK020593 – fundername: NCI NIH HHS grantid: R01 CA227481 – fundername: NCI NIH HHS grantid: K23 CA204726
GroupedDBID	--- .XZ 0R~ 29M 39C 53G 5S5 70F 7X7 88E 8FE 8FH 8FI 8FJ AARCD AASDW AAWTL AAWYQ AAYZH ABAWZ ABJNI ABLJU ABUWG ACGFS ADBBV AENEX AFANA AFFVI AFKRA AFSHS AGAYW AHBCP AHMBA AHOSX AHSBF AIBTJ ALFFA ALIPV ALMA_UNASSIGNED_HOLDINGS ALPWD ARMCB AXYYD BBNVY BENPR BHPHI BKKNO BPHCQ BVXVI CCPQU CGR CUY CVF DB5 EBS ECM EE. EIF EJD EXGXG F5P FQGFK FSGXE FYUFA HCIFZ HMCUK HZ~ IAO IGS IHR IHW INH INR ITC LK8 M1P M7P NFIDA NNMJJ NPM O9- ODYON OVD PHGZT PQQKQ PROAC PSQYO RNR RNT RNTTT S70 SHXYY SIXXV SNYQT SOJ TAOOD TBHMF TDRGL TEORI TSG UKHRP 3V. 7XB 8FK ABFSG ACSTC AEZWR AFHIU AGSTI AHWEU AIXLP ATHPR AZQEC DWQXO GNUQQ K9. PHGZM PJZUB PKEHL PPXIY PQEST PQGLB PQUKI PRINS 7X8 PUEGO
ID	FETCH-LOGICAL-c638t-29d7a08d66897cf74d70054cb742e38ba166b2c700bf8d77a77d1112c8b5fcb93
IEDL.DBID	M7P
ISICitedReferencesCount	274
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000641207400002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1759-5029 1759-5037
IngestDate	Thu Oct 02 12:07:41 EDT 2025 Tue Oct 07 07:12:57 EDT 2025 Thu Apr 03 07:06:20 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	7
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c638t-29d7a08d66897cf74d70054cb742e38ba166b2c700bf8d77a77d1112c8b5fcb93
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ORCID	0000-0002-6390-773X 0000-0002-2043-0150
OpenAccessLink	https://www.ncbi.nlm.nih.gov/pmc/articles/8769055
PMID	33875857
PQID	2541123490
PQPubID	2041936
PageCount	11
ParticipantIDs	proquest_miscellaneous_2515685593 proquest_journals_2541123490 pubmed_primary_33875857
PublicationCentury	2000
PublicationDate	2021-07-01
PublicationDateYYYYMMDD	2021-07-01
PublicationDate_xml	– month: 07 year: 2021 text: 2021-07-01 day: 01
PublicationDecade	2020
PublicationPlace	England
PublicationPlace_xml	– name: England – name: London
PublicationTitle	Nature reviews. Endocrinology
PublicationTitleAlternate	Nat Rev Endocrinol
PublicationYear	2021
Publisher	Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group
SSID	ssj0066474
Score	2.6825163
SecondaryResourceType	review_article
Snippet	Immune checkpoint inhibitors (ICIs) are monoclonal antibodies that target two key signalling pathways related to T cell activation and exhaustion, by binding...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	389
SubjectTerms	Adrenal glands Adverse events Antineoplastic Agents, Immunological - adverse effects Cancer Cell activation CTLA-4 protein Cytotoxicity Diabetes mellitus Drug-Related Side Effects and Adverse Reactions - epidemiology Drug-Related Side Effects and Adverse Reactions - immunology Endocrine disorders Endocrine System Diseases - chemically induced Endocrine System Diseases - diagnosis Endocrine System Diseases - epidemiology Endocrine System Diseases - therapy Epidemiology Humans Hypothyroidism Immune checkpoint inhibitors Immune Checkpoint Inhibitors - adverse effects Immune System - drug effects Immune System - physiology Immunotherapy Immunotherapy - adverse effects Lymphocytes T Monoclonal antibodies Morbidity Neoplasms - drug therapy Neoplasms - epidemiology Neoplasms - immunology Pancreas PD-1 protein Pembrolizumab Pituitary Signal transduction Thyroid Thyrotoxicosis
Title	Endocrine toxicities of immune checkpoint inhibitors
URI	https://www.ncbi.nlm.nih.gov/pubmed/33875857 https://www.proquest.com/docview/2541123490 https://www.proquest.com/docview/2515685593
Volume	17
WOSCitedRecordID	wos000641207400002&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEB6s9eDF96M-ygribWmapPs4iUqLBy1FFHorm31gEJNqo-i_d3ab6kkvXvaQhCHMzs7MNzsPgFOnubNKWGp1FNE0MZKqrutSEztuJFNRakKh8A0fDsV4LEd1wG1Wp1UudGJQ1KbUPkbeQSCDrkGSyuh8-kL91Ch_u1qP0GhA03dJiEPq3mihiRlLQxdmtJCS9qJY1kUzUSI6MzRcPKU-QcELcUqT313MYGoG6__9yQ1Yq51McjGXik1YssUWbF8UCLCfP8kZCWmfIZ6-DWm_QLq-BpBU5UeuQ4dVUjqS-8oRS3BT9dO0zIuK5MVjnuV-PM8OPAz691fXtB6lQDUesIrG0nAVCcOYkL4RUWq4d9Z0hsjYJiJTXcayWOPDzAnDueLcoBaMtch6Tmcy2YXloizsPhCmtNXWN64zCWJJRNDWWZZ1lZDozvRcC44WvJnU52E2-WFMC06-X6Mk--sJVdjyzX-DWFIg3aQFe3P-T6bzlhsTBNIe2PCDv4kfwmocttSn0x7BcvX6Zo9hRb9X-ey1DQ0-5mEVbWhe9oeju3YQGFyHo9svWNHGdw
linkProvider	ProQuest
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1LTxRBEK4QINELiCiuILaJeuswOz3bj4MxRCEQ1o0HTPY29vQjTIgzCzsI_Cl-o1W9u3jSGweuM5NOz9RX1fVNvQDeR6disDrw4LKMF8Ibbvuxz30elTfSZoVPhcJDNRrp8dh8X4K7RS0MpVUubGIy1L519I98D4kMugaiMNnnyQWnqVEUXV2M0JjB4iTcXiNlm346_ory_ZDnhwenX474fKoAd4i1jufGK5tpL6U21JOn8Ir8FlchSQxCV7YvZZU7vFhF7ZWySnk0CLnT1SC6ipovoclfQTuuiOyp8T3Bk7JIXZ_xRDZ8kOVmXqSTCb03xYNSFZwSIkhpCi7-7dKmo-1w_bF9lGewNnei2f4M9RuwFJrnsLnf2K79dcs-spTWmuIFm1AcNPgeVOPIuvamdqmDLGsjq6kyJjAErTuftHXTsbo5q6uaxg-9gB8Psv-XsNy0TXgFTFoXXKDGfF4gV9Zahxhk1bfaoLs2iD3YWciinOv7tPwriB68u7-NmkrhF9uE9oqeQa6scV3Rg62ZvMvJrKVIKYQm4qZe_3_xt_Dk6PTbsBwej0624Wme4ESpwzuw3F1ehTew6n539fRyNwGTwc-HFvofRbAePQ
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9NAEB5VKUJceJVHoMAiAbdVHO9mHweECk1E1SqKEEi9mfU-hIWwQ-MC_Wv8OmYcG05w64Grba3W_mbn4Zn5BuBZ8jpFZyKPPsu4FMFyN01THvKkg1Uuk6FrFD7Ry6U5PbWrHfg59MJQWeWgEztFHRpP_8gnGMigayCkzSapL4tYHS5erb9ymiBFmdZhnMZWRI7jxXcM3zYvjw4R6-d5vpi_f_OW9xMGuEe5a3lug3aZCUoZS_w8MmjyYXyJAWMUpnRTpcrc48UymaC10zqgcsi9KWfJl0TEhOp_V6OTIUew-3q-XL0b7IBSsuOARvts-SzLbd-ykwkz2aDZ1JJTeQQdIcnF3x3cztAtbvzPn-gmXO_da3awPQ-3YCfWt2HvoHZt8-WCvWBdwWuXSdgDOa_xnaj7kbXNj8p33LKsSayinpnIUJz953VT1S2r6k9VWdFgojvw4VL2fxdGdVPH-8CU89FHouwLAqNoY0xMUZVTZyw6crM0hv0Bl6LXBJviDyhjePr7Np5hSsy4Ojbn9AxG0QbXFWO4t8W-WG_JRgohDIV0-sG_F38CVxHr4uRoefwQruWdZFFN8T6M2rPz-Aiu-G9ttTl73Espg4-XjfovGJwoXQ
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Endocrine+toxicities+of+immune+checkpoint+inhibitors&rft.jtitle=Nature+reviews.+Endocrinology&rft.au=Wright%2C+Jordan+J&rft.au=Powers%2C+Alvin+C&rft.au=Johnson%2C+Douglas+B&rft.date=2021-07-01&rft.pub=Nature+Publishing+Group&rft.issn=1759-5029&rft.eissn=1759-5037&rft.volume=17&rft.issue=7&rft.spage=389&rft.epage=399&rft_id=info:doi/10.1038%2Fs41574-021-00484-3&rft.externalDBID=HAS_PDF_LINK
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1759-5029&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1759-5029&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1759-5029&client=summon